NEVO™ Sirolimus-eluting Coronary Stent System

DEVICE3 trials

Sponsors

Cordis US Corp.

Conditions

Atherosclerotic Coronary Artery DiseaseCoronary AtherosclerosisCoronary Disease

Phase 2

Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions

TerminatedNCT00714883

Cordis US Corp.Coronary Disease

Start: 2008-06-30End: 2012-10-31Updated: 2012-10-25

Phase 3

An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)

TerminatedNCT01202058

Cordis US Corp.Atherosclerotic Coronary Artery Disease

Start: 2010-08-31End: 2012-10-31Updated: 2012-10-25

Unknown Phase

Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

TerminatedNCT00606333

Cordis US Corp.Coronary Atherosclerosis

Start: 2008-03-31End: 2012-10-31Updated: 2012-10-25

Related Papers

Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions

EuroIntervention2013-10-0116 citations

Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.

2011-03-0811 citations

Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.

2010-11-0934 citations